You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 7, 2024

FERUMOXYTOL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Ferumoxytol patents expire, and what generic alternatives are available?

Ferumoxytol is a drug marketed by Sandoz and is included in one NDA.

The generic ingredient in FERUMOXYTOL is ferumoxytol. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the ferumoxytol profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Ferumoxytol

A generic version of FERUMOXYTOL was approved as ferumoxytol by SANDOZ on January 15th, 2021.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for FERUMOXYTOL?
  • What are the global sales for FERUMOXYTOL?
  • What is Average Wholesale Price for FERUMOXYTOL?
Drug patent expirations by year for FERUMOXYTOL
Drug Prices for FERUMOXYTOL

See drug prices for FERUMOXYTOL

Recent Clinical Trials for FERUMOXYTOL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Institutes of Health (NIH)Early Phase 1
Lipella Pharmaceuticals, Inc.Early Phase 1
Christopher J Chermansky, MDEarly Phase 1

See all FERUMOXYTOL clinical trials

Pharmacology for FERUMOXYTOL
Paragraph IV (Patent) Challenges for FERUMOXYTOL
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
FERAHEME Injection ferumoxytol 30 mg/mL, 17 mL single-use vials 022180 1 2015-12-04

US Patents and Regulatory Information for FERUMOXYTOL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sandoz FERUMOXYTOL ferumoxytol SOLUTION;INTRAVENOUS 206604-001 Jan 15, 2021 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for FERUMOXYTOL

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Takeda Pharma A/S Rienso ferumoxytol EMEA/H/C/002215
Rienso is indicated for the intravenous treatment of iron-deficiency anaemia in adult patients with chronic kidney disease (CKD).The diagnosis of iron deficiency must be based on appropriate laboratory tests (see section 4.2).
Withdrawn no no no 2012-06-15
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.